Specifically, the role of Th17 cells, a subpopulation of effector CD4+ helper T cells that produce IL-17A, in the effectiveness of glioma immunotherapy continues to be a subject of extensive discussion. The gene discussed is CD4; the disease is central nervous system cancer.